ST

Samantha Truex

Investor

Cambridge, Massachusetts

Overview

Work Experience

AT

Avalo Therapeutics

  • Board Member, Chair of Nom & Gov Committee

    2024 - Current

Artios

  • Board Member, Chair of Compensation Committee

    2022

UB

Upstream Bio

  • Chief Executive Officer

    2021 - 2024

HT

HotSpot Therapeutics, Inc.

  • Member of the Board; Chair of Audit Committee

    2018 - 2022

    Inspired by nature, HotSpot Therapeutics is moving beyond active site inhibition to allosterically target drivers of protein function and deliver first-in-class medicines with exceptional properties.

Quench Bio

  • CEO

    2018 - 2021

    Quench Bio sought to discover inhibitors of gasdermin, a novel target that plays a key role in inflammatory cell death. We aimed to provide effective therapies for patients with severe inflammatory diseases. Quench Bio raised a $50M Series A funded by Atlas Venture, RA Capital, Arix Bioscience and AbbVie Ventures. After almost 3 years of attempts to drug this interesting target, we wound down Quench and returned capital to the investors.

ST

Synlogic Therapeutics

  • COO and Head of Corporate Development

    2016 - 2017

    Led Corporate Development activities, including corporate/financing strategy, partnering, legal and operational alliances across manufacturing, research and development. Drove evaluation of financing options and executed on competitive reverse merger process culminating in signing of merger with Mirna in May 2017.

Padlock Therapeutics (now a subsidiary of Bristol-Myers Squibb)

  • Chief Business Officer

    2014 - 2016

    Padlock Therapeutics was acquired by Bristol-Myers Squibb (BMS) in 2016. Padlock Therapeutics was a venture-funded biotech company focused on developing therapeutic inhibitors of a family of enzymes called protein-arginine deiminases (PADs).

B

Biogen

  • VP Corporate Development

    2013 - 2014

  • VP, Program Executive for Fampyra

    2012 - 2013

  • Vice President, Business Development

    2010 - 2012

  • Sr. Director, Head of Product and Commercial Development for Hemophilia

    2008 - 2010

  • Sr. Director, Corporate Development

    2006 - 2008

    Head of Mergers and Acquisitions for Biogen Idec. Led M&A strategy/evaluations and interactions with investment bankers. Led acquisition of Syntonix in January 2007 and was instrumental in Biogen Idec sale process in Q4 2007.

G

Genzyme

  • Director, Business Development

    1998 - 2006

CC

Chiron Corporation

  • Associate, Business Development

    1997 - 1998

Education

Relevant Websites